Efficacy and safety of N-acetylcysteine in treatment of severe alcoholic hepatitis
Journal Title: Journal of Clinical Hepatology - Year 2024, Vol 40, Issue 12
Abstract
[Objective] To investigate the efficacy and safety of N-acetylcysteine （NAC） in the treatment of severe alcoholic hepatitis （SAH）， and to provide a basis for clinical medication for SAH. [Methods] A prospective randomized controlled trial was conducted among 172 SAH patients with a Maddrey discriminant function score of >32 points who were recruited by The Fifth Medical Center of Chinese PLA General Hospital from June 2015 to June 2018， and these patients were divided into NAC group with 84 patients and control group with 86 patients. NAC （8 g/day， 28 days） was assessed in terms of its safety in SAH patients， its impact on 28-day biochemical parameters， and its role in improving 28- and 180-day survival rates. A further analysis was performed to investigate the effect of NAC on the 28- and 180-day survival rates of SAH patients with acute-on-chronic liver failure （ACLF-SAH patients） and those without acute-on-chronic liver failure （non-ACLF-SAH patients）. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups. The Kaplan-Meier method was used to plot survival curves， and the Log-rank test was used for comparison of survival curves. Univariate and multivariate Cox proportional-hazards regression model analyses were used to investigate independent influencing factors. [Results] No serious adverse events were observed during NAC treatment， suggesting that NAC had a good safety profile. Compared with the control group， NAC did not significantly improve the 28-day biochemical parameters （all P>0.05） and survival rate of SAH patients （P=0.081）， but it could improve the 180-day survival rate of SAH patients （67.4% vs 81.0%， χ2=4.280， P=0.039）. NAC did not improve the 28- and 180-day survival rates of ACLF-SAH patients （both P>0.05）； NAC did not improve the 28-day survival rate of non-ACLF-SAH patients （P>0.05）， but it could improve the 180-day survival rate of these patients （68.4% vs 88.9%， χ2=4.883， P=0.027）. The multivariate Cox regression survival analysis showed that NAC treatment （hazard ratio ［HR］=2.530， 95% confidence interval ［CI］： 1.334 — 4.796， P=0.004，）， Maddrey discriminant function score （HR=3.852， 95%CI： 2.032 — 7.304， P<0.001）， and serum sodium level （HR=1.948， 95%CI： 1.079 — 3.517， P=0.027） were independent influencing factors for 180-day survival rate in SAH patients. [Conclusion] NAC has a good safety profile in the treatment of SAH and can improve the 180-day survival rate of SAH patients， and in particular， non-ACLF-SAH patients can benefit from NAC treatment in terms of middle- and long-term survival rates.
Authors and Affiliations
Fangjiao SONG, Tianjiao XU, Yirui YIN, Hua TIAN, Sa LYU, Shaoli YOU, Shaojie XIN, Bing ZHU
Keywords
Related Articles
- EP ID EP753946
- DOI 10.12449/JCH241219
- Views 22
- Downloads 0
Feasibility and safety of laparoscopic radical surgery for intrahepatic cholangiocarcinoma
Endoscopic techniques has been widely used in radical surgical resection of various tumors， but there are still controversies over the application of laparoscopy in radical treatment of intrahepatic cholangiocarcinoma....
Expression of CXCL10 and CXCL12 in gallbladder carcinoma and their mechanism of action in tumor invasion
[Objective] To investigate the expression levels of CXCL10 and CXCL12 in gallbladder carcinoma and their mechanism of action in tumor invasion. [Methods] Tumor tissue samples and adjacent tissue samples were collected fr...
Interpretation of guideline for diagnosis and treatment of liver failure （2024 version）
In 2024， Liver Failure and Artificial Liver Group， Chinese Society of Infectious Diseases， Chinese Medical Association and Chinese Society of Hepatology， Chinese Medical Association updated Guideline for diagnosis an...
Surgical treatment of gallbladder cancer： Current status and advances
Gallbladder cancer is a malignant tumor with an extremely poor prognosis， and radical surgery remains the only potentially curative treatment method for this disease. For stage Tis and T1a gallbladder cancer， cholecyst...
Immunological mechanism of drug-induced liver injury
Drug-induced liver injury （DILI） has a complex mechanism involving various pathways with a synergistic effect on each other and a causal relationship with each other， among which immune response plays an important rol...